Our metabolomics analysis of mutant IDH tumor samples indicated the significant reduction of carnitine and suppression of β-oxidation, which were the marked differences between the clinical samples and the cell lines (t-test, p < 0.05). The gene discussed is IDH2; the disease is neoplasm.